Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

FDA grants accelerated approval to Pfizer’s Elrexfio

August 15, 2023 Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval

Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …
News
lungs

FDA grants orphan drug designation to Genprex’s Reqorsa

August 15, 2023 Medical Communications FDA, ODD, Oncology, Reqorsa

Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …
News
pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023 Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
News
eye_2

Regeneron shares two-year PULSAR trial results for wAMD

August 11, 2023 Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD

Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …
News
eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023 Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …
News

FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment

August 3, 2023 Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho

Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …
News
Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023 Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …
News

FDA approves a second OTC naloxone nasal spray

July 31, 2023 Medical Communications FDA, Nasal Spray, OTC, OTC Products, naloxone, opioids

The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
News
vaccinessssssssssssssssssss_1

Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial

July 25, 2023 Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial

Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
News
Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023 Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
News

WHO releases Medical Product Alert for contaminated cough syrup

July 20, 2023 Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization

The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …
News

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023 Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …
News

FDA approves first OTC daily oral contraceptive pill

July 14, 2023 Medical Communications Contraception, FDA, OTC, Opill, contraceptive pill

The US Food and Drug Administration (FDA) has announced that it has approved the Opill (norgestrel) tablet for nonprescription use …
News
Chemotherapy

EMA accepts Astellas’ MAA for Zolbetuximab

July 14, 2023 Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …
News

ADC Therapeutics puts clinical trial enrollment on hold following patient deaths

July 12, 2023 Medical Communications ADC Therapeutics, DLBCL, Oncology, clinical trial

ADC Therapeutics has announced a voluntary pause in the enrollment of patients for its phase 2 LOTIS-9 clinical trial which …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025